Myriad maintained by Merrill Lynch at buy

Myriad Genetics Inc. was maintained by Merrill Lynch analyst David Munno at a buy rating with a price target on the stock of $24 per share following data from a follow-on portion of the phase II study of Flurizan for Alzheimer's. Myriad shares Friday were up $0.23, or 1.17%, at $19.91 on volume of 254,531 shares versus the three-month running average of 286,651 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.